Impact of ITH on PRAD patients and feasibility analysis of the positive correlation gene MYLK2 applied to PRAD treatment
IntroductionProstate adenocarcinoma (PRAD) is an extremely widespread site of urological malignancy and is the second most common male cancer in the world. Currently, research progress in immunotherapy for prostate treatment is slower compared to other tumours, which is mainly considered to be cause...
Saved in:
| Main Authors: | Chuanyu Ma, Guandu Li, Xiaohan Song, Xiaochen Qi, Tao Jiang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2025.1589259/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aurora kinase-a expression heterogeneity and potential benefit of combination therapy in prostate adenocarcinoma
by: Ru Chen, et al.
Published: (2025-07-01) -
MYLK-AS1 improves fracture by targeting miR-146a-5p to regulate cell viability and apoptosis in osteoblasts
by: Wuluhan Mahan, et al.
Published: (2025-03-01) -
Applicability of the regression approach for histological multi-class grading in clear cell renal cell carcinoma
by: Mayu Shibata, et al.
Published: (2025-03-01) -
DPH2 is a biomarker associated with cell death, immunity and prognosis based on pan-cancer analysis
by: Maolin Xiao, et al.
Published: (2025-02-01) -
The role of GSDMs in the immune microenvironment of prostate cancer and their impact on patient prognosis: a comprehensive analysis based on the TCGA-PRAD database
by: Kai Liu, et al.
Published: (2025-02-01)